IsoPlexis has received $2 million in grant funding from the National Cancer Institute’s Small Business Innovation Research Development Center for the advancement of intracellular proteomic pathway targeting solutions for single tumor cell analyses.
The grant provides funding for tools enabling the discovery of tumor resistance pathways using the IsoLight system, in the solid tumor clinical research area. IsoPlexis’ high multiplexed, single-cell, intracellular signaling pathway analysis tools provide a direct picture of the true proteomic pathway interactions in each tumor cell, resolving the masking of heterogeneity in bulk samples. more